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ORIGINAL ARTICLEBrain Electrical Activity Associated With Visual
Attention and Reactive Motor Inhibition in Patients
With Fibromyalgia
Alberto J. González-Villar, PhD, Manuel Arias, MD, PhD, and María Teresa Carrillo-de-la-Peña, PhDABSTRACTObjective: Fibromyalgia (FM) is a generalized chronic pain condition associated with multiple cognitive impairments, including altered
inhibitory processes. Inhibition is a key component of human executive functions and shares neural substrate with pain processing, which
may explain the inhibitory deficits in FM. Here, we investigated the integrity of brain inhibitory mechanisms in these patients.
Methods:We recorded the electroencephalographic activity of 27 patients with FM and 27 healthy controls (HCs) (all women) while they
performed a reactive motor inhibition task (the stop-signal paradigm). We analyzed task-induced modulations in electrophysiological
markers related to inhibition (N2, P3, and midfrontal theta oscillations) and visual attention (posterior alpha oscillations).
Results: The FM group performed the task correctly, with no differences relative to HCs at the behavioral level. We did not find any
between-group differences in N2 amplitude (F(1,52) = 0.01, p = .93), P3 amplitude (F(1,52) = 3.46; p = .068), or theta power
(F(1,52) = 0.05; p = .82). However, modulation of posterior alpha power after presentation of either the go or stop stimuli was lower in
patients than in HCs (F(1,52) = 7.98; p = .007).
Conclusions: N2, P3, theta power, and behavioral results indicate that the mechanisms of motor inhibition are sufficiently preserved to
enable correct performance of the stop-signal task in patients with FM. Nevertheless, the lower modulation of alpha suggests greater dif-
ficulty in mobilizing and maintaining visual attentional resources, a result that may explain the cognitive dysfunction observed in FM.
Key words: cognitive dysfunction, electroencephalography, fibromyalgia, motor inhibition.BDI = Beck Depression Inventory, BMI = body mass index, EEG =
electroencephalogram, ERP = event-related potentials, FM = fibro-
myalgia, FSQ = fibromyalgia survey questionnaire, HC = healthy
control,MAOI=monoamine oxidase inhibitor,MFE-30=Memory
Failures of Everyday Questionnaire, NSAID = nonsteroidal anti-
inflammatory drug, PCA = principal components analysis, PCS = Pain
Catastrophizing Scale, SARIs = serotonin antagonist and reuptake in-
hibitor, SSD = stop-signal delay, SNRI = serotonin-norepinephrine
reuptake inhibitor, SSRI = selective serotonin reuptake inhibitor,
SSRT = stop-signal reaction time, SSS = Symptom Severity Score,
TCA = tricyclic antidepressant, TF = temporal factor, VAS = visual
analogue scale, WPI = Widespread Pain IndexINTRODUCTION
F ibromyalgia (FM) is a chronic syndrome involving widespreadpain, fatigue, sleep disorders, and cognitive dysfunction. Cogni-
tive dysfunction complaints are approximately 2.5 times more fre-
quent in patients with FM than in chronic pain patients affected by
different rheumatic conditions and have a major impact on the pa-
tients' quality of life (1–3). Cognitive alterations in patients with FM
have been found in different dimensions such as attention, executive
function, as well as working, semantic, and episodic memory (4,5).
Execution of an organized cognitive or behavioral response re-
quires well-preserved inhibitorymechanisms (6). Inhibition, a type
of executive function, allows humans to stop unwanted behavior
and to eliminate undesired mental representations (7). Previous
studies have reported alterations in behavioral indices or neuroim-
aging data associated with motor response inhibition, suggesting
changes in frontal networks related to executive functioning in
FM (8–11). Nevertheless, evidence for motor inhibition deficits
in patients with FM remains scarce and sometimes contradictory,
because abnormalities are not always observed at the behavioral
level (10,11). Furthermore, although alterations inmotor inhibition
have been detected using proactive motor inhibition tasks (go/no-go),
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Psychosomatic Medicine, V 00 • 00-00 1patients with FM while they perform reactive inhibition tasks (such
as the stop-signal task).
The stop-signal task requires the immediate cancellation of an
already initiated motion plan after the presentation of a stop signal.
Although the mechanisms involved in emotional-motivational
control of pain-related information are different from those in-
volved in motor inhibition, the simplicity in operationalizing the
latter makes the stop-signal task a useful tool for studying inhibi-
tion processes in FM (12). In this line, recent reports have sug-
gested a direct relationship between the capacity to tolerate
induced pain and the ability to perform tasks that require motorlty of Psychology, Universidade de Santiago de Compostela, Spain; Psycho-
hool of Psychology, Universidade do Minho, Portugal; Departamento de
de Compostela, Spain.
e Santiago de Compostela, Santiago de Compostela, Galicia SPAIN. E-mail:
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TABLE 1. Sociodemographic and Clinical Variables for Patients
With FM and HCs
FM HC Statistics
Age, y 49.9 (9.6) 50.0 (10.5) t(52) = −0.76; p = .45
Years of education 10.7 (3.4) 10.6 (3.1) t(52) = −0.13; p = .90
BMI 24.2 (4.2) 25.8 (5.6) t(52) = −1.14; p = .26
PCS 23.0 (14.7) 12.0 (8.9) t(52) = 3.2; p = .002
BDI 21.5 (11.7) 8.6 (4.6) t(52) = 5.2; p < .001
VAS pain 6.3 (1.6) 2.2 (2.3) t(52) = 7.4; p < .001
VAS mood 5.4 (2.8) 2.9 (2.4) t(52) = 3.8; p < .001
FSQ2 1.96 (0.76) 0.85 (.67) t(52) = 5.7; p < .001
SSS 9.2 (1.9) 3.8 (2.2) t(52) = 9.37; p < .001
WPI 12.1 (4.1) 2.0 (2.0) t(52) = 11.6; p < .001














FM = fibromyalgia; HC = healthy control; BMI = body mass index; PCS = Pain
Catastrophizing Scale; BDI = Beck Depression Inventory; VAS = visual analogue scale;
FSQ2 = Item 2 of the Fibromyalgia Survey Questionnaire; SSS = Symptom Severity
Score; WPI = Widespread Pain Index; MFE-30 = Memory Failures of Everyday
Questionnaire; SSRIs = selective serotonin reuptake inhibitors; TCAs = tricyclic
antidepressants; SNRIs = serotonin-norepinephrine reuptake inhibitors;
SARIs = serotonin antagonist and reuptake inhibitors; MAOIs = monoamine oxidase
inhibitors; NSAIDs = nonsteroidal anti-inflammatory drugs.
Mean (SD) values for each measured variable are provided.
ORIGINAL ARTICLEinhibition (13,14). Conversely, people with a lower inhibitory ca-
pacity may show increasing and sustained pain avoidance re-
sponses, which may contribute to the pain becoming chronic
(15). Thus, although the existing evidence suggests that the pres-
ence of chronic pain may be related to alterations in inhibition pro-
cesses, this relationship has not been yet explored using a reactive
motor inhibition task in FM.
At the electroencephalographic level, the stop-signal tasks
evoke the appearance of event-related potential (ERP) components
such as N2 and P3. These components have their neural origin in
medial and fronto-central cortical areas, and they are related to
conflict detection and inhibition evaluation, respectively (16–18).
In the frequency domain, inhibition is associated with an increase
in midfrontal theta power, oscillatory activity that is also associ-
ated with the N2 and P3 components (19). Moreover, performance
of the stop-signal task requires adequate involvement of visual at-
tention mechanisms, which is associated with a reduction in poste-
rior alpha power (20,21).
To further investigate the possible alterations in motor inhibi-
tion mechanisms, we recorded the brain electrical activity of pa-
tients with FM while they performed the stop-signal task. We
hypothesized that patients have slower reaction times and
make more inhibition errors than healthy controls (HCs). We also
expected to find differences in the amplitude of N2 and P3 ERP
components, both associated with motor inhibition. Given the dif-
ficulty in interpreting these components because of the overlap-
ping activity related to the go and stop signals (22), we applied
temporal principal component analysis (PCA) to the ERP data to
better differentiate between the activity evoked by each of the sig-
nals. We also included an electroencephalogram (EEG) index ob-
tained by time-frequency decomposition (midfrontal theta), which
has been related to cognitive control and motor inhibition. Finally,
we investigated modulation of the posterior alpha power after
stimulus presentation to explore the integrity of visual attention
processes during the performance of the stop-signal task and its re-
lationship with clinical variables.
METHODS
Participants
Twenty-seven patients with FM and 27 HCs (all women in both groups)
participated in the study. The patients were recruited from a local hospital
(Complexo Hospitalario Universitario de Santiago) and from patients' associ-
ations in Santiago de Compostela (Spain) and surrounding areas. All patients
were diagnosed by a physician and fulfilled the 1990 and 2010 American
College of Rheumatology criteria for diagnosis of FM (23,24). HCs were re-
cruited through advertisements placed in community centers. From the initial
sample (35 FMs and 35 HCs), three patients with FM and three controls were
excluded from the analysis for having extreme proportions (<0.1 to >0.9) of
correct inhibitions during the stop-signal task. Five patients with FM and four
HCs were excluded because of insufficient quality of the EEG recordings.
One additional control participant was excluded because of self-reported high
levels of pain. See Table 1 for sociodemographic and clinical data. The initial
sample used in this study is the same as that described in a previous article
(25). Registration sessions were conducted between June 2014 and May
2015. The study was approved by the ethics committee of the University of
Santiago in accordance with the Declaration of Helsinki. All healthy volun-
teers and patients were informed about the experimental procedures and gave
written informed consent before participation.
All participants were interviewed about their health status and assessed
for pain levels and other symptoms of FM. They completed visual analoguePsychosomatic Medicine, V 00 • 00-00 2scales (VAS) to assess pain level andmood state during the last month. Par-
ticipants also completed the Pain Catastrophizing Scale (PCS) (26,27) and
the Beck Depression Inventory (BDI) (28,29), with cut-off scores as fol-
lows: 0–9minimal depression; 10–18mild depression; 19–29moderate de-
pression; and 30–63 severe depression. The Widespread Pain Index (WPI)
and the Symptom Severity Score (SSS) were also obtained using the Span-
ish version of the Fibromyalgia Survey Questionnaire (FSQ) (23,30). Item
2 of the FSQ scale was used to assess the presence of cognitive complaints
(scored from 0, no problems, to 3, severe problems). Cognitive complaints
were also assessed using the total score of the Memory Failures of Every-
day Questionnaire (MFE-30) (31). The MFE-30 is composed of 30 items
to evaluate subjective memory complaints. Each item is rated on a five-
point Likert-type scale ranging from 0 to 4, making a total score between
0 and 120. Cut-off scores are as follows: 0–7 optimal performance;
8–35 normal performance; 36–50 mild deterioration; and >50 moderate
or severe mnesic deterioration. The MFE-30 was only applied to
24 patients with FM and 19 HCs, and therefore, the statistical analyses
including this questionnaire were done with fewer participants.
Task and Procedure
The participants were fitted with an electrode cap for EEG recording and
were seated facing a 17-in monitor (viewing distance, 80 cm) on which
the stimuli were presented. The participants were asked to fix their sightMonth 2019
Reactive Motor Inhibition in Fibromyalgiain the center of the screen and to avoid moving their heads during the task.
The recording sessions were conducted in an electrically isolated roomwith
low light and noise levels.
The stop-signal task involved presentation of arrows pointing right or
left (Figure 1). All arrowswere first blue and then changed to green, yellow,
or red (all colors with the same level of luminance). The first arrowwas pre-
sented for 500 milliseconds and the color change occurred at an interval
(also called Stop-Signal Delay [SSD]) of between 150 and 350 millisec-
onds, with 50-millisecond steps. The SSD interval was determined using
the staircase-tracking algorithm, which increased by 50 milliseconds if
the previous stop trial was correctly inhibited and decreased the SSD by
50 milliseconds if the previous stop trial was not inhibited. This algorithm
causes a distribution approximately 1/2 of successful and 1/2 of unsuccess-
ful inhibited trials. The participants were asked to respond quickly with the
index finger of the hand on the side to which the arrow was pointing. If the
arrow changed to red, they had to immediately stop their response, but if the
arrow changed to green or yellow, they had to continue responding. A fix-
ation cross with a random duration between 1.8 and 2 seconds was shown
during the interstimulus interval.
The task consisted of 240 trials, 80 of which were stop trials (red ar-
row). Participants had five breaks of undetermined duration and were able
to resume the task whenever they wished. All participants completed 10
practice trials to ensure that they understood the instructions. The task
was designed and presented using PsychoPy software (32).EEG Recording and Data Analysis
EEG activity was recorded via 32 active electrodes inserted in an electrode
cap (following the 10–20 international system). Vertical and horizontal eye
movements were registered using four additional surface electrodes. The
FP1 electrode was used as reference and FPz as ground. Impedances were
kept less than 10 KΩ. The signal was recorded at a sampling rate of 500 Hz
and filtered with an on-line band-pass filter (0.1–100 Hz) and a notch filter
(50 Hz). A Brain Vision actiCHamp amplifier was used for recording.
The EEG data were analyzed using EEGlab 13.3 software (33). Chan-
nels with low-quality recordings were removed and replaced by sphericalFIGURE 1. Design of the stop-signal task. Each trial began with a blue
or yellow in the go trials (2/3) or red in the stop trials (1/3). The particip
of the arrow and to stop their response if the arrow changed to red. The
2 seconds. Color image is available only in online version (www.psyc
Psychosomatic Medicine, V 00 • 00-00 3spline interpolation (with less than 0.01% interpolated electrodes in each
group). The segments with prominent ocular artefacts were removed after
visual inspection. The EEG was resampled and filtered using a high-pass
FIR filter at 0.5 Hz and low-pass FIR filter at 30 Hz. Epochs were extracted
from −800 to 1800 milliseconds, time locked to the color change of the ar-
row. The periods analyzed were therefore not based on the initial arrow but
rather on the moment when the color changes, and the trial is confirmed as
go or stop. For FM participants, the M (SD) number of epochs retained was
147.6 (10.6) in the go condition and 78.3 (2.1) in the stop condition,
whereas for HCs, the M (SD) was 148.8 (12.4) and 78.1 (7.6), respectively,
with no difference between the two groups (F(1,52) = 0.07; p = .8). An ex-
tended version of the independent component analysis was applied, and the
components associated with eye movements or muscular activity were
manually removed. The EEG was re-referenced using the reference elec-
trode standardization technique method (34). This method allows the
EEG to be transformed from an initial reference in any location to a virtual
point located at infinity, which is an ideal location for a neutral reference,
because it is far from the influence of neural or noisy electrical activity.
For the ERPs, the baseline was corrected using an interval between −450
and − 350 milliseconds before the stop or go signals were displayed. This
interval was chosen because there may be activity after −350 milliseconds
evoked by the presentation of the first arrow.
After the ERPs were averaged, we performed a temporal PCA (tPCA)
using the ERP PCA toolkit (35). tPCA enables separation of temporarily
overlapping components, thus simplifying the analysis and description of
complexmultidimensional data. This technique produces a series of tempo-
ral factors (TFs) free from the influence of nearby components, and it en-
ables elimination of subjective influences in the identification of ERP
peaks. A scree test was used to select the number of factors to be retained
(36). The results of the scree test indicated that six factors, together account-
ing for 93% of the variance, should be retained. Factors were extracted on
the basis of the covariance matrix (Promax rotation). The components were
then reconstructed to microvolt units by multiplying the factor loads by the
factor scores for each electrode, participant, and condition. The peak ampli-
tude (measured in the electrode that showed the largest amplitude of each
component) was used for statistical comparisons. Of the six componentsarrow pointing to the right or left. The arrow then changed to green
ants were required to respond as quickly as possible to the direction
interval between stimuli was of variable duration between 1.8 and
hosomaticmedicine.org).
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ORIGINAL ARTICLEextracted,wedidnot analyzeTF4, because the latencywasvery late (852millisec-
onds) and was not associated with any of the expected factors. The remain-
ing factors are described in the results section.
Time-frequency decomposition of the EEG was performed by comput-
ing the inverse fast Fourier transform of the multiplication of the power
spectrum of the EEG data by the power spectrum of different complex
Morlet wavelets. Wavelets were created in 25 logarithmically frequency
spaced steps (3–35 Hz), with 3 cycles at the lowest frequency up to 8 at the
highest frequency, also in logarithmically increasing steps. Event-related spec-
tral perturbation was normalized by transforming the power change of each
time-frequency pixel to decibel, relative to the mean power in the baseline
interval (−600 to −400 milliseconds) for each frequency. We selected elec-
trodes FC1 and FC2 for analysis of the theta band as well as electrodes O1
and O2 for analysis of alpha activity, i.e., the locations where these oscilla-
tions usually showmaximum power modulation (37).We carried out statis-
tical analysis of the mean power in the time-frequency window where the
modulation was greatest.
With regard to behavioral data, we computed the mean reaction time,
the percentage of successfully stopped trials, and the stop-signal reaction
time (SSRT). SSRT is an index of the speed of the stopping process, and
here, we calculated it by subtracting the mean SSD from the mean go reac-
tion time for each participant (38).
Statistical Analysis
Differences between groups in sociodemographic variables, measures of
FM symptoms, and behavioral data (reaction times, the percentage of suc-
cessfully stopped trials and SSRT) were analyzed using t tests for indepen-
dent samples. Repeated-measures analyses of variance were applied to the
electrophysiological data (factors obtained by tPCA and theta and alpha
power) with the factors group (FM or HC) and condition (go or stop trials).
The Greenhouse-Geisser correction was applied to adjust the degrees of
freedom of the F values when the assumption of sphericity was not ful-
filled. Effect sizes are reported using Hedges's gs for independent samples
t test and η2p for repeated-measures analyses of variance. The Spearman's
rank correlation coefficients were computed to assess the relationship between
alpha power modulation and sociodemographic and symptomatic variables.
Correlations were corrected for multiple comparisons using the false discovery
rate procedure. All statistical analyses were performed using SPSS 20.
RESULTS
Behavioral Data
Both groups performed similarly at the behavioral level, with no
differences in RTs for either the go trials (FM: 590 ± 79 milliseconds;
HC: 584 ± 72milliseconds; t(52) = 0.3; p = .76; Hedges's gs = .078) or
the unsuccessfully inhibited stop trials (FM: 502 ± 63 milliseconds;
HC: 503 ± 58milliseconds; t(52) = −0.08; p = .94; Hedges's gs = .016).
There were also no between-group differences in the percent-
age of successfully stopped trials (FM=56± 22%;HC=55 ± 21%;
t(52) = 0.28; p = .78; Hedges's gs = .072) or in the complementary
unsuccessfully stopped trials (same nonsignificant results). No dif-
ferences were observed either for the SSRT (FM = 334 ± 81 milli-
seconds; HC = 328 ± 73%; t(52) = 0.35; p = .73; Hedges's
gs = .090).
Electrophysiological Data
We obtained the following results for the TFs extracted after
the tPCA.
TF1: The first TF peak measured via the CP2 electrode (the lo-
cation where it showed its maximum value) occurred at 504 milli-
seconds and was thus related to the P3 component (Figure 2).
Although patients showed less amplitude in this factor, there werePsychosomatic Medicine, V 00 • 00-00 4no significant between-group differences (FM: 2.5 ± 2.5 μV; HC:
3.7 ± 2.9 μV; F(1,52) = 3.46; p = .068; η2p = .062). Condition had a
main effect on TF1 (F(1,52) = 18.9; p < .001; η2p = .267) with a
higher amplitude in stop than in go trials (go: 2.5±2.6 μV; stop:
3.7±2.8 μV). The group by condition interaction was not signifi-
cant (F(1,52) = 1.04; p = .31; η2p = .02).
TF2: The peak activity of this factor—with positive polarity—
was measured via the F8 electrode at 116 milliseconds. Given its
negative polarity at central electrodes and its latency, TF2 seems
to be related to the ERP component N2. No between-group differ-
ences were observed for this factor (FM: 1.7 ± 2.3 μV; HC:
1.6 ± 2.1 μV; F(1,52) = 0.01; p = .93; η2p < .001), whereas condi-
tion had a significant main effect (F(1,52) = 40.9; p < .001; η2p =
.441), with higher amplitude in stop than go trials (go: 1.3 ±
2.2 μV; stop: 2.0 ± 2.2 μV). The group by condition interaction
was not significant (F(1,52) = 2.2; p = .14; η2p = .041).
TF3: The peak activity was recorded via the P8 electrode at 364
milliseconds. Given that the peak activity is detected by posterior
electrodes, this component seems to be related to the visual pro-
cessing of the stimulus. No between-group differences were ob-
served for this factor (FM: −2.5 ± 2.9 μV; HC: −2.5 ± 2.4 μV;
F(1,52) = 0.0; p = .99; η2p < .001). Condition had a significant main
effect (F(1,52) = 67.8; p < .001; η2p = .566), with higher amplitude
in stop trials (go: −1.7 ± 2.3 μV; stop: −3.3 ± 2.7 μV). The group
by condition interaction was not significant (F(1,52) = 0.05;
p = .82; η2p = .001).
TF5: The peak activity was recorded via the FT10 electrode at
−36 milliseconds. Because of its negative latency, this factor
seemed to be related to the brain activity evoked by presentation
of the first arrow. There were no between-group differences in
the amplitude of TF5 (FM: 1.2 ± 0.9 μV; HC: 1.5 ± 1.0 μV;
F(1,52) = 0.66; p = .42; η2p = .013). Condition did not have a sig-
nificant effect (go: 1.3 ± 1.0 μV; stop: 1.4 ± 0.9 μV; F(1,52) = 1.8;
p = .18; η2p = .034), and the group by condition interaction was not
significant either (F(1,52) = 2.3; p = .13; η2p = .043).
TF6: The maximum amplitude of this factor was recorded via
the O2 electrode at 184 milliseconds, and it therefore seems to
be related to the visual processing of the second stimulus. No
between-group differences were observed (FM: −2.0 ± 1.6 μV;
HC: −2.5 ± 2.6 μV; F(1,52) = 0.58; p = .45; η2p = .011). However,
the amplitude was higher in the stop trials than in the go trials (go:
−2.1 ± 1.9 μV; stop: −2.4 ± 2.4 μV; F(1,52) = 5.32; p = .025; η2p =
.093). The group by condition interaction was not significant
(F(1,52) = 0.6; p = .44; η2p = .011).
Regarding the time-frequency data, an increase in midfrontal
theta power (FC1 and FC2 electrodes; from 200 to 500milliseconds
and 3 to 6 Hz) was observed in both groups, with no significant dif-
ference between them (FM: 3.6 ± 1.4 dB; HC: 3.7 ± 1.1 dB;
F(1,52) = 0.05; p = .82; η2p = .001). Theta power modulation
was higher in stop than in go trials (go: 3.2 ± 1.4 dB; stop:
4.1 ± 1.4 dB; F(1,52) = 43.87; p < .001; η2p = .458). The group
by condition interaction was not significant (F(1,52) = 0.85; p =
.36; η2p = .016). See Figure 3.
Finally, modulation of posterior alpha power (O1 and O2 elec-
trodes; from300 to 600milliseconds and 9 to 13Hz)was significantly
lower in patients with FM than in controls (FM: −0.4 ± 1.6 dB; HC:
−1.6 ± 1.8 dB; F(1,52) = 7.98; p = .006; η2p = .133). In addition, al-
pha modulation was higher in stop than in go trials (go: −0.8 ± 1.6;
stop: −1.3 ± 1.8; F(1,52) = 9.65; p = .003; η2p = .157). The groupMonth 2019
FIGURE 2. Event-related potentials and temporal principal component analyses. A left, Averaged ERPs obtained from patients with FM
and HCs in go and stop trials recorded in the Cz electrode. A right, Time course of the factors extracted after tPCA. B, Time course and
topography of each TF analyzed. FM = fibromyalgia; HC = healthy controls; TF = temporal factor. Color image is available only in online
version (www.psychosomaticmedicine.org).
Reactive Motor Inhibition in Fibromyalgiaby condition interaction was not significant (F(1,52) = 0.01; p =
.93; η2p < .001).
Given that the power of alpha was sensitive to between-group
differences, we verified the extent to which this index was re-
lated to sociodemographic and clinical variables by computing
the Spearman's rank correlations (Table 2 and Figure 4). Alpha
power was positively correlated with variables such as painPsychosomatic Medicine, V 00 • 00-00 5catastrophizing, depression, both VAS (measuring level of pain
and mood), the level of cognitive dysfunction, the SSS, and the
widespread pain index. Lower modulation of alpha power (lower
power reduction) was therefore associated with more severity in
these clinical variables. Note that these correlations were calculated
using both groups together. When calculating the correlations using
the FM group alone, only a marginally significant correlationMonth 2019
FIGURE 3. Time-frequency analyses. Left, Spectrograms of the evoked activity in the electrodes FC1/FC2 (top) and O1/O2 (bottom).
Middle, Time course of the theta power (3–6 Hz) and alpha power (9–13 Hz) bands obtained from patients with FM and HCs. Right,
Topographies of the theta activity between 200 and 500 milliseconds (top box) and the alpha activity between 300 and 600
milliseconds (bottom box) for each group and condition. FM = fibromyalgia; HC = healthy controls. Color image is available only in
online version (www.psychosomaticmedicine.org).
ORIGINAL ARTICLEappears (alpha power for Go trials and SSS; r = .385; p = .047),
which did not survive the false discovery rate correction.
DISCUSSION
Little is known about possible motor inhibition alterations in pa-
tients experiencing chronic pain. Because inhibitory control is cru-
cial for correcting inappropriate behavior and has been related to
pain tolerance, we investigated whether FM patients show dys-
function in motor inhibition processes. We found that patients
with FM did not show any behavioral alteration in reactive mo-
tor inhibition during performance of a stop-signal task. In addi-
tion, the brain electrical activity related to inhibition processes
(N2, P3, and midfrontal theta) was not different in FM and in
HCs. However, we found that modulation of posterior alpha
power during the stimuli processing was lower in the patients
with FM than in the controls. These findings suggest that pa-
tients with FM preserve sufficient cognitive capacity to cor-
rectly perform a reactive motor inhibition task, although they
show alterations during the initiation of mechanisms related to




Alpha (go trials) −.10 (.5) −.01 (.9) −.10 (.5) .28 (.039) .33 (.017)* .
Alpha (stop trials) −.06 (.6) −.08 (.5) −.19 (.2) .30 (.029) .41 (.003)*
BMI = body mass index; PCS = Pain Catastrophizing Scale; BDI = Beck Depression Inve
Questionnaire; SSS = Symptom Severity Score.
Spearman's rank correlations were calculated by merging both groups of participants. The
significant after false discovery rate correction (p value used for threshold = .023).
Psychosomatic Medicine, V 00 • 00-00 6Patients Maintain Their Ability to Inhibit Initiated
Motor Responses
FM patients frequently complain of emotional and cognitive prob-
lems, alterations that can even be physiologically manifested and
induce somatic symptoms (39,40). The bulk of the evidence sup-
ports the presence of deficiencies in different processes, such as atten-
tion, executive functioning, and working memory (41,42). However,
some contradictory results have been reported (43,44). Moreover, de-
spite the various arguments suggesting a link between chronic pain
and inhibitory deficits, there is a lack of knowledge about the in-
tegrity of inhibitory circuits in those patients and particularly in
FM. People with better inhibitory control can tolerate higher levels
of pain, suggesting a relationship between inhibition and pain per-
ception (45). Nevertheless, no studies have explored processes of
reactive motor inhibition in FM using the stop-signal task.
In the present study, the results did not confirm any behavioral
difference between patients and HCs in the stop-signal task and
thus indicate that the inhibitory mechanisms during the execution
of simple tasks that require response cancellation to an external
stimulus are not altered in FM. This result is consistent with someal Variables
VAS Pain VAS Mood FSQ2 SSS WPI MFE-30
31 (.023)* .34 (.013)* .39 (.004)* .36 (.008)* .22 (.11) .40 (.008)*
.28 (.044) .32 (.017)* .39 (.004)* .40 (.003)* .26 (.056) .35 (.020)*
ntory; VAS = visual analogue scale; FSQ2 = Item 2 of the Fibromyalgia Survey
p values are shown between parentheses. The p values with an asterisk remained
Month 2019
FIGURE 4. Scatter plots for correlations between alpha power and clinical variables. Regression lines (computed using least-squares
method) are only shown in significant correlations. PCS = Pain Catastrophizing Scale; BDI = Beck Depression Inventory; VAS = visual
analogue scale; FSQ2 = Item 2 of the Fibromyalgia Survey Questionnaire; SSS = Symptom Severity Score; WPI = Widespread Pain
Index; MFE = Memory Failures of Everyday Questionnaire; FM = Fibromyalgia Group; HC = Healthy Controls Group. Color image is
available only in online version (www.psychosomaticmedicine.org).
Reactive Motor Inhibition in Fibromyalgiaof the previous research findings observed using proactive motor
inhibition tasks (go/no-go) in patients with FM (10,11).
We applied temporal principal components analysis to the ERP
data to better differentiate between the brain activity related to in-
hibitory processes and that related to the perceptual processing of
stimuli. We also performed time-frequency analysis, which pro-
vides information on the power modulation of oscillatory activity
and enables better characterization of brain functioning. The N2
and midfrontal theta indexes both presumably reflect the detection
of conflict during motor inhibition (46). They seem to be origi-
nated in fronto-central brain locations (47,48), which play a signif-
icant role in both nociceptive processing and motor inhibition (49).
No between-group differences were found in either the TF identi-
fied as N2 nor the theta power. The P3 component is another char-
acteristic ERP elicited during stop-signal tasks. The neural origin
of this component seems to be located in areas such as the mid-
cingulate cortex and the inferior frontal cortex (17,50,51), and it
is interpreted as the cognitive evaluation of the motor inhibition (16).
Again, although themean P3 amplitudewas smaller in patients, the dif-
ference relative toHCswas not significant. Similarly, no between-group
differenceswere observed for any of the remaining TFs extracted. Alto-
gether, the results show no alterations in reactive motor inhibition—at
either behavioral or electrophysiological level—in the patients, suggest-
ing adequate functioning of frontal inhibitory neural networks in FM.Psychosomatic Medicine, V 00 • 00-00 7The ERP findings contrast with the alterations in neuroimaging
data observed in patients with FM during motor inhibition (10,11).
Rather than the stop-signal paradigm, these studies used a proac-
tive inhibition task (go/no-go). Both tasks probably involve over-
lapping but distinct neural networks, given that the stop-signal
task implies cancellation of an already prepared response and cre-
ates greater inhibitory pressure than the go/no-go task (12,52). The
present findings also differ from those we have previously obtained,
i.e., alterations of midfrontal theta activity during the execution of
tasks that require cognitive control and the maintenance of top-
down attention, such as the Multi-Source Interference Task and
the n-back working memory task (25,53). A possible explanation,
as other studies have stressed, is that the differences between pa-
tients and controls are more evident during tasks with a higher cog-
nitive load (54) or with an added source of distraction (55). As
already mentioned, the lack of differences at both behavioral and
electrophysiological levels may be due to the simplicity of the
stop-signal task, and thus, the alterations may be more evident in
tasks that require higher and sustained top-down attentional control.
Patients Show Impaired Modulation of Posterior
Alpha Oscillations
The only electrophysiological marker that indicated significant
between-group differences was posterior alpha power. The lowerMonth 2019
ORIGINAL ARTICLEmodulation of alpha power in the FM group occurred in both stop
and go trials, suggesting that this alteration is not exclusively re-
lated to motor inhibition, but to the deployment of visual-spatial
attention during the task. Numerous studies have reported a rela-
tionship between the reduction in alpha power and visual informa-
tion perception and task execution (56,57). This finding supports
the hypothesis that the cognitive dysfunction reported in FM
may be related to difficulties in maintaining the levels of visual at-
tention required for correct task performance. These patients seem
to be more vulnerable to distraction and have difficulty managing
different sources of simultaneous information or coping with com-
plex and unstable environments (38,58). Attention-related problems
have previously been described in FM (54,59) and explained by the
competition with pain, which is thought to capture attentional re-
sources and make such resources less available for performance
of other tasks (60).
The alpha power data apparently contrast with the lack of dif-
ferences in TF 6, which also seem to be related to the activation
of visual areas. Nevertheless, they are different measures, because
ERPs provide information on phase-locked activity linked to the
processing of the stimuli, whereas time-frequency data show power
modulation in both phase-locked and nonphase-locked activity.
Thus, given that time-frequency analyses provide information on
power changes sustained over time, our findings suggest that pa-
tients with FM do not have deficits in the perceptual processing
of the stimuli, but rather experience difficulty inmaintaining sustained
visual cortical activation.
As expected, patients reported higher disturbance in the usual
symptoms of FM, such as pain, depression, catastrophizing, and
cognitive dysfunction. Interestingly, these variables were corre-
lated with the alpha power. Thus, higher scores for depression, cat-
astrophizing, cognitive dysfunction, or pain were associated with
lower modulation of alpha power. This finding suggests that the
ability to deploy visual attentional resources is affected by the se-
verity of symptoms frequently reported in FM and indicates that
alpha power modulation may be used as an index of FM symptom
and used for monitoring therapy interventions.Limitations
One limitation of this study stems from the confounding effects of
the medication consumed by patients with FM (mainly nonsteroi-
dal anti-inflammatory drugs, antidepressants, anxiolytics, and
pregabalin/gabapentin). Although some of these drugs affect the
central nervous system, it is not known how they influence the re-
sults (61). Although medication can reduce the level of attention
and thus worsen task performance, it can also restore sleep and re-
duce pain levels, thus possibly improving task execution. On the
other hand, selection of patients who do not consume medication
or the temporary withdrawal of medication would cause limita-
tions because of selection bias and the effects of the temporary re-
striction, respectively.
Another limitation is that the results obtained with a simple re-
active motor inhibition task cannot be applied to other inhibition
processes in FM. Nevertheless, because reactive motor inhibition
may use overlapping circuits with other types of inhibition, such
as emotional and motivational control (12), the study findings
may contribute to our understanding of possible alterations in
FM. Furthermore, as we have already mentioned, there seems toPsychosomatic Medicine, V 00 • 00-00 8be a relationship between the ability to inhibit motor responses and
the capacity to cope with pain (13). Use of this task thus represents
a first step in the study of altered inhibition of patients with FM, pro-
viding a simplemeasure to assess the integrity of inhibitory processes.
CONCLUSIONS
We demonstrated that patients with FM maintain the capacity to
perform a reactive motor inhibition task. The brain activity associ-
ated with inhibitory mechanisms was also similar in patients and
controls, suggesting that motor inhibition mechanisms are conserved,
or at least at a sufficient degree for correct performance of this type
of task. However, modulation of posterior alpha power was lower
in the FM group after stimulus presentation; this index was signif-
icantly correlated with the severity of FM symptoms. These results
suggest that patients with FM show a deficit in the initiation and
maintenance of attentional resources associated with the process-
ing of visual stimuli and that the cognitive dysfunction may be ex-
plained by relatively weaker organization of visual cortical processing.
Treatments capable of modulating posterior alpha activity (e.g.,
medication, noninvasive brain stimulation, or psychological treat-
ment) may be useful for improving cognitive deficits and thus the
quality of life of patients with FM.
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